{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T14:44:20Z","timestamp":1784040260696,"version":"3.55.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T00:00:00Z","timestamp":1684540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T00:00:00Z","timestamp":1684540800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Metastasis"],"published-print":{"date-parts":[[2023,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Limited data are available to guide the decision-making process for clinicians and their patients regarding palliative treatment options for patients with isolated synchronous colorectal cancer peritoneal metastases (CRC-PM). Therefore, the aim of this study is to analyze the outcome of the different palliative treatments for these patients. All patients diagnosed with isolated synchronous CRC-PM between 2009 and 2020 (Netherlands Cancer Registry) who underwent palliative treatment were included. Patients who underwent emergency surgery or curative intent treatment were excluded. Patients were categorized into upfront palliative primary tumor resection (with or without additional systemic treatment) or palliative systemic treatment only. Overall survival (OS) was compared between both groups and multivariable cox regression analysis was performed. Of 1031 included patients, 364 (35%) patients underwent primary tumor resection and 667 (65%) patients received systemic treatment only. Sixty-day mortality was 9% in the primary tumor resection group and 5% in the systemic treatment group (<jats:italic>P<\/jats:italic>\u2009=\u20090.007). OS was 13.8 months in the primary tumor resection group and 10.3 months in the systemic treatment group (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001). Multivariable analysis showed that primary tumor resection was associated with improved OS (HR 0.68; 95%CI 0.57\u20130.81; <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001). Palliative primary tumor resection appeared to be associated with improved survival compared to palliative systemic treatment alone in patients with isolated synchronous CRC-PM despite a higher 60-day mortality. This finding must be interpreted with care as residual bias probably played a significant role. Nevertheless, this option may be considered in the decision-making process by clinicians and their patients.<\/jats:p>","DOI":"10.1007\/s10585-023-10212-y","type":"journal-article","created":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T08:01:46Z","timestamp":1684569706000},"page":"289-298","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Primary tumor resection or systemic treatment as palliative treatment for patients with isolated synchronous colorectal cancer peritoneal metastases in a nationwide cohort study"],"prefix":"10.1007","volume":"40","author":[{"given":"Anouk","family":"Rijken","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent C. J.","family":"van de Vlasakker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geert A.","family":"Simkens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koen P.","family":"Rovers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felice N.","family":"van Erning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Koopman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cornelis","family":"Verhoef","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes H. W.","family":"de Wilt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignace H. J. T.","family":"de Hingh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,20]]},"reference":[{"key":"10212_CR1","unstructured":"World Health Organisation. Global Cancer Observatory. Accessed April 1 (2022) https:\/\/gco.iarc.fr\/today\/home"},{"issue":"11","key":"10212_CR2","doi-asserted-by":"publisher","first-page":"2717","DOI":"10.1002\/ijc.25596","volume":"128","author":"VE Lemmens","year":"2011","unstructured":"Lemmens VE, Klaver YL, Verwaal VJ et al (2011) Predictors and survival of synchronous peritoneal carcinomatosis of colorectal origin: a population-based study. Int J Cancer 128(11):2717\u20132725. https:\/\/doi.org\/10.1002\/ijc.25596","journal-title":"Int J Cancer"},{"issue":"5","key":"10212_CR3","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1016\/j.ejso.2020.11.135","volume":"47","author":"RJ Lurvink","year":"2021","unstructured":"Lurvink RJ, Bakkers C, Rijken A et al (2021) Increase in the incidence of synchronous and metachronous peritoneal metastases in patients with colorectal cancer: a nationwide study. Eur J Surg Oncol 47(5):1026\u20131033. https:\/\/doi.org\/10.1016\/j.ejso.2020.11.135","journal-title":"Eur J Surg Oncol"},{"issue":"12","key":"10212_CR4","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1097\/DCR.0b013e3182a62d9d","volume":"56","author":"I Thomassen","year":"2013","unstructured":"Thomassen I, van Gestel YR, Lemmens VE et al (2013) Incidence, prognosis, and treatment options for patients with synchronous peritoneal carcinomatosis and liver metastases from colorectal origin. Dis Colon Rectum 56(12):1373\u20131380. https:\/\/doi.org\/10.1097\/DCR.0b013e3182a62d9d","journal-title":"Dis Colon Rectum"},{"issue":"13","key":"10212_CR5","doi-asserted-by":"publisher","first-page":"9073","DOI":"10.1245\/s10434-021-10190-z","volume":"28","author":"C Bakkers","year":"2021","unstructured":"Bakkers C, Lurvink RJ, Rijken A et al (2021) Treatment strategies and prognosis of patients with synchronous or metachronous colorectal peritoneal metastases: a Population-Based study. Ann Surg Oncol 28(13):9073\u20139083. https:\/\/doi.org\/10.1245\/s10434-021-10190-z","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"10212_CR6","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/s41572-021-00326-6","volume":"7","author":"D Cort\u00e9s-Guiral","year":"2021","unstructured":"Cort\u00e9s-Guiral D, H\u00fcbner M, Alyami M et al (2021) Primary and metastatic peritoneal surface malignancies. Nat Rev Dis Primers 7(1):91. https:\/\/doi.org\/10.1038\/s41572-021-00326-6","journal-title":"Nat Rev Dis Primers"},{"issue":"2","key":"10212_CR7","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/S1470-2045(20)30599-4","volume":"22","author":"F Qu\u00e9net","year":"2021","unstructured":"Qu\u00e9net F, Elias D, Roca L et al (2021) Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol 22(2):256\u2013266. https:\/\/doi.org\/10.1016\/S1470-2045(20)30599-4","journal-title":"Lancet Oncol"},{"issue":"11","key":"10212_CR8","doi-asserted-by":"publisher","first-page":"3660","DOI":"10.1245\/s10434-016-5247-7","volume":"23","author":"FJ Amelung","year":"2016","unstructured":"Amelung FJ, Consten ECJ, Siersema PD et al (2016) A Population-Based analysis of three treatment modalities for malignant obstruction of the proximal Colon: Acute Resection Versus Stent or Stoma as a bridge to surgery. Ann Surg Oncol 23(11):3660\u20133668. https:\/\/doi.org\/10.1245\/s10434-016-5247-7","journal-title":"Ann Surg Oncol"},{"issue":"9","key":"10212_CR9","doi-asserted-by":"publisher","first-page":"2082","DOI":"10.1002\/ijc.30240","volume":"139","author":"J \u2019t Lam-Boer","year":"2016","unstructured":"\u2019t Lam-Boer J, van der Geest LG, Verhoef C et al (2016) Palliative resection of the primary tumor is associated with improved overall survival in incurable stage IV colorectal cancer: a nationwide population-based propensity-score adjusted study in the Netherlands. Int J Cancer 139(9):2082\u20132094. https:\/\/doi.org\/10.1002\/ijc.30240","journal-title":"Int J Cancer"},{"key":"10212_CR10","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.ejca.2017.12.014","volume":"91","author":"KL van Rooijen","year":"2018","unstructured":"van Rooijen KL, Shi Q, Goey KKH et al (2018) Prognostic value of primary tumour resection in synchronous metastatic colorectal cancer: individual patient data analysis of first-line randomised trials from the ARCAD database. Eur J Cancer 91:99\u2013106. https:\/\/doi.org\/10.1016\/j.ejca.2017.12.014","journal-title":"Eur J Cancer"},{"issue":"7","key":"10212_CR11","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1002\/cncr.30230","volume":"123","author":"Z Alawadi","year":"2017","unstructured":"Alawadi Z, Phatak UR, Hu CY et al (2017) Comparative effectiveness of primary tumor resection in patients with stage IV colon cancer. Cancer 123(7):1124\u20131133. https:\/\/doi.org\/10.1002\/cncr.30230","journal-title":"Cancer"},{"issue":"2","key":"10212_CR12","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.ejca.2014.10.023","volume":"51","author":"M Faron","year":"2015","unstructured":"Faron M, Pignon JP, Malka D et al (2015) Is primary tumour resection associated with survival improvement in patients with colorectal cancer and unresectable synchronous metastases? A pooled analysis of individual data from four randomised trials. Eur J Cancer 51(2):166\u2013176. https:\/\/doi.org\/10.1016\/j.ejca.2014.10.023","journal-title":"Eur J Cancer"},{"key":"10212_CR13","doi-asserted-by":"publisher","first-page":"16516","DOI":"10.1038\/srep16516","volume":"5","author":"H Xu","year":"2015","unstructured":"Xu H, Xia Z, Jia X et al (2015) Primary tumor resection is Associated with Improved Survival in Stage IV Colorectal Cancer: an Instrumental Variable Analysis. Sci Rep 5:16516. https:\/\/doi.org\/10.1038\/srep16516","journal-title":"Sci Rep"},{"issue":"3","key":"10212_CR14","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1007\/s11605-017-3617-5","volume":"22","author":"S Maroney","year":"2018","unstructured":"Maroney S, Chavez de Paz C, Reeves ME et al (2018) Benefit of Surgical Resection of the primary tumor in patients undergoing chemotherapy for stage IV Colorectal Cancer with Unresected Metastasis. J Gastrointest Surg 22(3):460\u2013466. https:\/\/doi.org\/10.1007\/s11605-017-3617-5","journal-title":"J Gastrointest Surg"},{"issue":"4","key":"10212_CR15","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1097\/DCR.0000000000000546","volume":"59","author":"BC Gulack","year":"2016","unstructured":"Gulack BC, Nussbaum DP, Keenan JE et al (2016) Surgical Resection of the primary tumor in Stage IV Colorectal Cancer without Metastasectomy is Associated with Improved overall survival compared with Chemotherapy\/Radiation Therapy alone. Dis Colon Rectum 59(4):299\u2013305. https:\/\/doi.org\/10.1097\/DCR.0000000000000546","journal-title":"Dis Colon Rectum"},{"issue":"7","key":"10212_CR16","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1097\/COC.0000000000000823","volume":"44","author":"DEW van der Kruijssen","year":"2021","unstructured":"van der Kruijssen DEW, Brouwer NPM, van der Kuil AJS et al (2021) Interaction between primary tumor resection, primary Tumor Location, and Survival in Synchronous Metastatic Colorectal Cancer: a Population-Based study. Am J Clin Oncol 44(7):315\u2013324. https:\/\/doi.org\/10.1097\/COC.0000000000000823","journal-title":"Am J Clin Oncol"},{"issue":"1","key":"10212_CR17","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1186\/1471-2407-14-741","volume":"14","author":"J \u2019t Lam - Boer","year":"2014","unstructured":"\u2019t Lam - Boer J, Mol L, Verhoef C et al (2014) The CAIRO4 study: the role of surgery of the primary tumour with few or absent symptoms in patients with synchronous unresectable metastases of colorectal cancer\u2013a randomized phase III study of the dutch Colorectal Cancer Group (DCCG). BMC Cancer 14(1):741. https:\/\/doi.org\/10.1186\/1471-2407-14-741","journal-title":"BMC Cancer"},{"issue":"12","key":"10212_CR18","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1001\/jamasurg.2021.4992","volume":"156","author":"DEW van der Kruijssen","year":"2021","unstructured":"van der Kruijssen DEW, Elias SG, Vink GR et al (2021) Sixty-day mortality of patients with metastatic colorectal Cancer randomized to systemic treatment vs primary Tumor Resection followed by systemic treatment: the CAIRO4 phase 3 Randomized Clinical Trial. JAMA Surg 156(12):1093\u20131101. https:\/\/doi.org\/10.1001\/jamasurg.2021.4992","journal-title":"JAMA Surg"},{"issue":"10","key":"10212_CR19","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1200\/JCO.20.02447","volume":"39","author":"Y Kanemitsu","year":"2021","unstructured":"Kanemitsu Y, Shitara K, Mizusawa J et al (2021) Primary Tumor Resection Plus Chemotherapy Versus Chemotherapy alone for colorectal Cancer patients with asymptomatic, synchronous unresectable metastases (JCOG1007; iPACS): a Randomized Clinical Trial. J Clin Oncol 39(10):1098\u20131107. https:\/\/doi.org\/10.1200\/JCO.20.02447","journal-title":"J Clin Oncol"},{"issue":"8","key":"10212_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cancers12082306","volume":"12","author":"EJ Park","year":"2020","unstructured":"Park EJ, Baek JH, Choi GS et al (2020) The role of primary Tumor Resection in Colorectal Cancer patients with asymptomatic, synchronous, unresectable metastasis: a Multicenter Randomized Controlled Trial. Cancers (Basel) 12(8):1\u201314. https:\/\/doi.org\/10.3390\/cancers12082306","journal-title":"Cancers (Basel)"},{"issue":"12","key":"10212_CR21","doi-asserted-by":"publisher","first-page":"3252","DOI":"10.1245\/s10434-011-1951-5","volume":"18","author":"S Venderbosch","year":"2011","unstructured":"Venderbosch S, de Wilt JH, Teerenstra S et al (2011) Prognostic value of resection of primary tumor in patients with stage IV colorectal cancer: retrospective analysis of two randomized studies and a review of the literature. Ann Surg Oncol 18(12):3252\u20133260. https:\/\/doi.org\/10.1245\/s10434-011-1951-5","journal-title":"Ann Surg Oncol"},{"issue":"5","key":"10212_CR22","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1007\/s10585-015-9719-0","volume":"32","author":"LGM van der Geest","year":"2015","unstructured":"van der Geest LGM, Lam-Boer J, Koopman M et al (2015) Nationwide trends in incidence, treatment and survival of colorectal cancer patients with synchronous metastases. Clin Exp Metastasis 32(5):457\u2013465. https:\/\/doi.org\/10.1007\/s10585-015-9719-0","journal-title":"Clin Exp Metastasis"},{"issue":"12","key":"10212_CR23","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1016\/S1470-2045(16)30500-9","volume":"17","author":"J Franko","year":"2016","unstructured":"Franko J, Shi Q, Meyers JP et al (2016) Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the analysis and research in cancers of the Digestive System (ARCAD) database. Lancet Oncol 17(12):1709\u20131719. https:\/\/doi.org\/10.1016\/S1470-2045(16)30500-9","journal-title":"Lancet Oncol"},{"issue":"10","key":"10212_CR24","doi-asserted-by":"publisher","first-page":"2250","DOI":"10.1093\/annonc\/mdq762","volume":"22","author":"YLB Klaver","year":"2011","unstructured":"Klaver YLB, Lemmens VEPP, Creemers GJ et al (2011) Population-based survival of patients with peritoneal carcinomatosis from colorectal origin in the era of increasing use of palliative chemotherapy. Ann Oncol 22(10):2250\u20132256. https:\/\/doi.org\/10.1093\/annonc\/mdq762","journal-title":"Ann Oncol"},{"issue":"7","key":"10212_CR25","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1016\/j.ejso.2012.03.008","volume":"38","author":"YLB Klaver","year":"2012","unstructured":"Klaver YLB, Simkens LHJ, Lemmens VEPP et al (2012) Outcomes of colorectal cancer patients with peritoneal carcinomatosis treated with chemotherapy with and without targeted therapy. Eur J Surg Oncol 38(7):617\u2013623. https:\/\/doi.org\/10.1016\/j.ejso.2012.03.008","journal-title":"Eur J Surg Oncol"},{"issue":"suppl 3","key":"10212_CR26","doi-asserted-by":"publisher","first-page":"S61","DOI":"10.1016\/S0959-8049(11)70148-4","volume":"47","author":"C Verhoef","year":"2011","unstructured":"Verhoef C, de Wilt JH, Burger JWA et al (2011) Surgery of the primary in stage IV colorectal cancer with unresectable metastases. Eur J Cancer 47(suppl 3):S61\u2013S66. https:\/\/doi.org\/10.1016\/S0959-8049(11)70148-4","journal-title":"Eur J Cancer"},{"issue":"1","key":"10212_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1245\/s10434-021-10949-4","volume":"29","author":"T Konishi","year":"2022","unstructured":"Konishi T, Rodriguez-Bigas MA (2022) Primary Tumor Resection in Colorectal Cancer with Unresectable Synchronous Metastasis: time to reconsider the role of the Surgeon. Ann Surg Oncol 29(1):1\u20133. https:\/\/doi.org\/10.1245\/s10434-021-10949-4","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"10212_CR28","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1001\/jamasurg.2014.2253","volume":"150","author":"CY Hu","year":"2015","unstructured":"Hu CY, Bailey CE, You YN et al (2015) Time trend analysis of primary tumor resection for stage IV colorectal cancer: less surgery, improved survival. JAMA Surg 150(3):245\u2013251. https:\/\/doi.org\/10.1001\/jamasurg.2014.2253","journal-title":"JAMA Surg"},{"key":"10212_CR29","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1186\/1471-2407-12-142","volume":"12","author":"NN Rahbari","year":"2012","unstructured":"Rahbari NN, Lordick F, Fink C et al (2012) Resection of the primary tumour versus no resection prior to systemic therapy in patients with colon cancer and synchronous unresectable metastases (UICC stage IV): SYNCHRONOUS\u2013a randomised controlled multicentre trial (ISRCTN30964555). BMC Cancer 12:142. https:\/\/doi.org\/10.1186\/1471-2407-12-142","journal-title":"BMC Cancer"},{"issue":"suppl 17","key":"10212_CR30","doi-asserted-by":"publisher","first-page":"LBA3507","DOI":"10.1200\/JCO.2022.40.17_suppl.LBA3507","volume":"40","author":"NN Rahbari","year":"2022","unstructured":"Rahbari NN, Biondo S, Fei\u03b2t M et al (2022) Randomized clinical trial on resection of the primary tumor versus no resection prior to systemic therapy in patients with colon cancer and synchronous unresectable metastases. J Clin Oncol 40(suppl 17):LBA3507. https:\/\/doi.org\/10.1200\/JCO.2022.40.17_suppl.LBA3507","journal-title":"J Clin Oncol"},{"issue":"4","key":"10212_CR31","doi-asserted-by":"publisher","first-page":"359","DOI":"10.6004\/jnccn.2018.0021","volume":"16","author":"AB Benson","year":"2018","unstructured":"Benson AB, Venook AP, Al-Hawary MM et al (2018) NCCN Guidelines Insights: Colon cancer, Version 2.2018. J Natl Compr Canc Netw 16(4):359\u2013369. https:\/\/doi.org\/10.6004\/jnccn.2018.0021","journal-title":"J Natl Compr Canc Netw"},{"issue":"6","key":"10212_CR32","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1007\/s00261-008-9464-9","volume":"35","author":"D Marin","year":"2010","unstructured":"Marin D, Catalano C, Baski M et al (2010) 64-Section multi-detector row CT in the preoperative diagnosis of peritoneal carcinomatosis: correlation with histopathological findings. Abdom Imaging 35(6):694\u2013700. https:\/\/doi.org\/10.1007\/s00261-008-9464-9","journal-title":"Abdom Imaging"},{"issue":"9","key":"10212_CR33","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1002\/bjs.10527","volume":"104","author":"A Dohan","year":"2017","unstructured":"Dohan A, Hoeffel C, Soyer P et al (2017) Evaluation of the peritoneal carcinomatosis index with CT and MRI. Br J Surg 104(9):1244\u20131249. https:\/\/doi.org\/10.1002\/bjs.10527","journal-title":"Br J Surg"},{"issue":"12","key":"10212_CR34","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1038\/s41416-022-01742-5","volume":"126","author":"J Laoukili","year":"2022","unstructured":"Laoukili J, Constantinides A, Wassenaar ECE et al (2022) Peritoneal metastases from colorectal cancer belong to Consensus Molecular Subtype 4 and are sensitised to oxaliplatin by inhibiting reducing capacity. Br J Cancer 126(12):1824\u20131833. https:\/\/doi.org\/10.1038\/s41416-022-01742-5","journal-title":"Br J Cancer"},{"issue":"3","key":"10212_CR35","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1002\/ijc.32750","volume":"147","author":"KD van der Willik","year":"2020","unstructured":"van der Willik KD, Ruiter R, van Rooij FJA et al (2020) Ascertainment of cancer in longitudinal research: the concordance between the Rotterdam Study and the Netherlands Cancer Registry. Int J Cancer 147(3):633\u2013640. https:\/\/doi.org\/10.1002\/ijc.32750","journal-title":"Int J Cancer"}],"container-title":["Clinical &amp; Experimental Metastasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10585-023-10212-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10585-023-10212-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10585-023-10212-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,12]],"date-time":"2023-07-12T04:04:29Z","timestamp":1689134669000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10585-023-10212-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,20]]},"references-count":35,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["10212"],"URL":"https:\/\/doi.org\/10.1007\/s10585-023-10212-y","relation":{},"ISSN":["0262-0898","1573-7276"],"issn-type":[{"value":"0262-0898","type":"print"},{"value":"1573-7276","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,20]]},"assertion":[{"value":"29 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr. Koopman reported having an advisory role for Nordic Farma, Merck-Serono, Pierre Fabre, Servier, Institutional scientific grants from Bayer, Bristol Myers Squibb, Merck, Personal Genome Diagnostics (PGDx), Pierre Fabre, Roche, Sirtex, Servier. Dr. de Wilt reported an unrestricted research grant from Medtronic and Roche, outside the submitted work, paid to the institute. Dr. de Hingh reported an unrestricted research grant from RanD\/QPS and Roche, outside the submitted work, paid to the institute. For the remaining authors none were declared.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}